Direct‐acting antivirals for chronic hepatitis C

BACKGROUND: Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct‐acting antivirals (DAAs), e.g. sofosbuvir, are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cochrane Database Syst Rev
Autors principals: Jakobsen, Janus C, Nielsen, Emil Eik, Feinberg, Joshua, Katakam, Kiran Kumar, Fobian, Kristina, Hauser, Goran, Poropat, Goran, Djurisic, Snezana, Weiss, Karl Heinz, Bjelakovic, Milica, Bjelakovic, Goran, Klingenberg, Sarah Louise, Liu, Jian Ping, Nikolova, Dimitrinka, Koretz, Ronald L, Gluud, Christian
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2017
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6484376/
https://ncbi.nlm.nih.gov/pubmed/28922704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012143.pub3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars